Importantly, in a recent study, researchers found that in breast cancer cells with acquired letrozole resistance, the constitutive activation of the AKT/mTOR pathway could be blocked by PI3K and/or mTOR inhibitors, but not by EGFR/ErbB2 inhibitors [2]. The gene discussed is AKT1; the disease is breast cancer.